Cambridge Healthtech Institute’s Inaugural 

Technology-Driven Oncology Clinical Development 

Biomarkers and Strategies for Combination Therapy and Immunotherapy

February 16-18, 2015 | Moscone North Convention Center | San Francisco, CA
Part of the 22nd Annual Molecular Medicine Tri-Conference

 

The series of failures of cancer therapies in late stages of clinical development forced us to look for new and innovative strategies of cancer therapy in general and cancer clinical development in particular. Clinical development scientists are working hard to keep up with the recent discoveries in cancer biology as well as with the genomic technologies available to advance clinical development strategies. The Technology-Driven Oncology Clinical Development conference, part of the 22nd International Molecular Medicine Tri-Conference, is designed to discuss the latest advances in combination therapy and cancer immunotherapy research, and to search for solutions and strategies that allow to match clinical development with these advances.


NGS-DRIVEN NEXT-GENERATION STRATIFIED TRIALS

Lung MAP Trial: Protocol Design and Stratification Techniques

David Gandara, M.D., Professor of Medicine, Division of Hematology/Oncology, University of California, Davis School of Medicine; Director, Thoracic Oncology Program, Senior Advisor to the Director, UC Davis Comprehensive Cancer Center; Chair, Lung Committee, Southwest Oncology Group (SWOG)

The Evolving Genotype-to-Phenotype Paradigm in Oncology Drug Development

Steffan N. Ho, M.D., Ph.D., Senior Director, Early Development, Translational Oncology, Pfizer Oncology

NGS-Based Companion Testing in Biomarker-Driven Clinical Trials

Shirin Khambata Ford, Ph.D., Executive Director, US Hematology and Oncology Medical Affairs, Celgene Corporation


TRANSLATIONAL APPROACHES IN CANCER IMMUNOTHERAPY DEVELOPMENT

Biomarkers in Cancer Immunotherapy

Ira Mellman, M.D., Vice President, Cancer Immunology, Genentech

Strategies for Clinical Development of Cancer Immunotherapy

Roy Baynes, M.D., Senior Vice President, Global Clinical Development, Merck

Translational Strategies for the Clinical Development of Immunomodulatory Antibodies

Robert Pierce, M.D., CMO, OncoSec Medical, Inc.

Preclinical Validation of Immunotherapies and Combination Strategies for Cancer

James Smothers, Ph.D., Senior Director, Head, Discovery, Immuno-Oncology & Combinations DPU, Oncology R&D, GlaxoSmithKline


PRACTICAL ASPECTS OF IMPLEMENTING THE MASTER PROTOCOL

Correlative Studies and Specimen Analysis in the Squamous Cell Carcinoma Master Protocol

Philip C. Mack, Ph.D., Associate Adjunct Professor, Internal Medicine, Hematology and Oncology, University of California Davis Medical Center

Match Protocol Development

P. Mickey Williams, Ph.D. (contractor), Director, Molecular Characterization Laboratory (aka MoCha), Frederick National Laboratory for Cancer Research


PATIENT RECRUITMENT USING BIOMARKER ANALYSIS TOOLS

Demonstration of the Utility of Point-of-Care Genotyping Technologies to Actively Recruit into Genotype Stratified Studies

Charles Cox, Ph.D., Head, Genetics Experiment Design and Delivery, GlaxoSmithKline

Survival Improvement by Personalized Genomic Diagnostics for Ovarian Cancer Chemotherapy

Jae Lee, Ph.D., Chair and Senior Member, Biostatistics and Bioinformatics, Moffitt Cancer Center


TRANSLATIONAL APPROACHES TO CHILDHOOD CANCER

Preclinical Childhood Cancer Models for Developing Molecularly Targeted Therapies.

Peter Houghton, Ph.D., Director, Center for Childhood Cancer, The Research Institute, Nationwide Children’s Hospital

The Institutes for Molecular Medicine at Phoenix Children’s Hospital to Address the Unmet Need: Slow Progress in Pediatric Drug Development

Nazneen Aziz, Ph.D., Senior Vice President & Chief Research Officer, Phoenix Children's Hospital

Suggested Event Package:

February 16 Morning Short Course: Using PDX and Other Preclinical Models in Oncology to Inform First-Man-Trial Design: Tools and Techniques

February 19-20 Symposia: Cancer Immunotherapy 



For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com 

 

 

  2015 Plenary Sessions 

2015 MMTC Prelim Agenda 

Premier Sponsors:

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex 

Thomson Reuters-Large 


Local Partners:

BayBio 


biocube 


Cabs 

City of SSF